Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens
Status: Enrolling
Updated:  2/5/2016
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens
Status: Enrolling
Updated: 2/5/2016
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens
Status: Enrolling
Updated:  2/5/2016
Edmond Odette Cancer Centre at Sunnybrook
mi
from
Toronto,
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens
Status: Enrolling
Updated: 2/5/2016
Edmond Odette Cancer Centre at Sunnybrook
mi
from
Toronto,
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
La Jolla, CA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
San Francisco, CA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Aurora, CO
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Lakeland, FL
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Lakeland, FL
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Orlando, FL
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Park Ridge, IL
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Indianapolis, IN
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Lutherville, MD
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Lutherville, MD
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Boston, MA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
St. Louis, MO
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Lebanon, NH
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Morristown, NJ
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Buffalo, NY
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
New York, NY
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Charlotte, NC
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Columbus, OH
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Houston, TX
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Madison, WI
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
mi
from
Brisbane,
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
mi
from
Brisbane,
Click here to add this to my saved trials
Vascular CT Assessment of Structural Autograft and Allograft Healing
Vascular CT Assessment of Structural Autograft and Allograft Healing
Status: Enrolling
Updated:  2/8/2016
University of Rochester
mi
from
Rochester, NY
Vascular CT Assessment of Structural Autograft and Allograft Healing
Vascular CT Assessment of Structural Autograft and Allograft Healing
Status: Enrolling
Updated: 2/8/2016
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
LC Drug Eluting Bead for Regional Chemoembolization to Downstage Unresectable Hepatocellular Carcinoma (HCC) to Liver Transplantation
Status: Enrolling
Updated:  2/8/2016
UPMC Liver Cancer Center, Montefiore 7 South, 3459 Fifth Avenue
mi
from
Pittsburgh, PA
LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
LC Drug Eluting Bead for Regional Chemoembolization to Downstage Unresectable Hepatocellular Carcinoma (HCC) to Liver Transplantation
Status: Enrolling
Updated: 2/8/2016
UPMC Liver Cancer Center, Montefiore 7 South, 3459 Fifth Avenue
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)
A Phase II Trial of 3 Dimensional Proton Radiotherapy With Concomitant Chemotherapy for Patients With Initially Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/8/2016
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)
A Phase II Trial of 3 Dimensional Proton Radiotherapy With Concomitant Chemotherapy for Patients With Initially Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/8/2016
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated:  2/8/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated: 2/8/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated:  2/8/2016
Clinical Research Facility
mi
from
Greenbrae, CA
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated: 2/8/2016
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated:  2/8/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated: 2/8/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated:  2/8/2016
Clinical Research Facility
mi
from
Fort Meyers, FL
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated: 2/8/2016
Clinical Research Facility
mi
from
Fort Meyers, FL
Click here to add this to my saved trials
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated:  2/8/2016
Clinical Research Facility
mi
from
Detriot, MI
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated: 2/8/2016
Clinical Research Facility
mi
from
Detriot, MI
Click here to add this to my saved trials
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated:  2/8/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
Status: Enrolling
Updated: 2/8/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase I/II Trial to Establish the Safety and Preliminary Efficacy of the Combination of Docetaxel, Prednisone, and SOM 230 (Pasireotide) in Metastatic Castrate Resistant Prostate Cancer (CRPC).
Status: Enrolling
Updated:  2/8/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase I/II Trial to Establish the Safety and Preliminary Efficacy of the Combination of Docetaxel, Prednisone, and SOM 230 (Pasireotide) in Metastatic Castrate Resistant Prostate Cancer (CRPC).
Status: Enrolling
Updated: 2/8/2016
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Status: Enrolling
Updated:  2/8/2016
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Status: Enrolling
Updated: 2/8/2016
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Click here to add this to my saved trials
Analysis of Blood During Surgery for Musculoskeletal Tumors
Cellular Analysis of Blood Suctioned During Surgery for Musculoskeletal Tumors
Status: Enrolling
Updated:  2/8/2016
University Hospital
mi
from
Newark, NJ
Analysis of Blood During Surgery for Musculoskeletal Tumors
Cellular Analysis of Blood Suctioned During Surgery for Musculoskeletal Tumors
Status: Enrolling
Updated: 2/8/2016
University Hospital
mi
from
Newark, NJ
Click here to add this to my saved trials
Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU
Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU
Status: Enrolling
Updated:  2/8/2016
UPMC Center for Innovation in Restorative Medicine
mi
from
Pittsburgh, PA
Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU
Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU
Status: Enrolling
Updated: 2/8/2016
UPMC Center for Innovation in Restorative Medicine
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas
Pilot Study of Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  2/8/2016
Medical University of South Carolina
mi
from
Charleston, SC
Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas
Pilot Study of Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 2/8/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation
Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation
Status: Enrolling
Updated:  2/8/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation
Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation
Status: Enrolling
Updated: 2/8/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Enrolling
Updated:  2/9/2016
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Enrolling
Updated: 2/9/2016
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer
Status: Enrolling
Updated:  2/9/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer
Status: Enrolling
Updated: 2/9/2016
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
A Phase I Trial of Hydroxychloroquine in Combination With Temsirolimus in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  2/9/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
A Phase I Trial of Hydroxychloroquine in Combination With Temsirolimus in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 2/9/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy
A Phase I Blinded, Randomized Feasibility Trial of Dietary Flaxseed Administration in Non-Small Cell Lung Cancer Patients Receiving Definitive Thoracic Chemoradiotherapy
Status: Enrolling
Updated:  2/9/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy
A Phase I Blinded, Randomized Feasibility Trial of Dietary Flaxseed Administration in Non-Small Cell Lung Cancer Patients Receiving Definitive Thoracic Chemoradiotherapy
Status: Enrolling
Updated: 2/9/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors
Status: Enrolling
Updated:  2/9/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors
Status: Enrolling
Updated: 2/9/2016
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  2/9/2016
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 2/9/2016
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  2/9/2016
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 2/9/2016
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  2/9/2016
The Hospital of Central Connecticut
mi
from
New Britain, CT
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 2/9/2016
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials